Dec 28, 2025
Retinal Vein Occlusion: Risk Factors and Injections Explained
Understand the difference between FDA priority and standard ANDA reviews. Learn how GDUFA III timelines, first-generic exclusivity, and new domestic manufacturing pilots impact your approval speed and revenue.